Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma

David Gau, Pooja A. Chawla, Kexin Xu, Niharika Welling, Jacob Antonello, Carla Consoli, Monica Wei, Sara Zdancewicz, Maria Fernanda Laranjeira‐Silva, Chris Varghese, Paul Francoeur, Haibin Shi, Xucai Chen, Anurag N. Paranjape, Flordeliza S. Villanueva, Thomas E. Smithgall, Andrew P. VanDemark, David Ryan Koes, Donna M. Huryn, Partha Roy

TL;DR

Researchers have developed a targeted strategy to "starve" kidney cancer tumors by disrupting the interaction between the protein profilin1 (Pfn1) and actin. By optimizing a lead small molecule and delivering it via ultrasound-triggered microbubbles, the team successfully reduced tumor blood vessel growth (angiogenesis) and slowed tumor progression in mouse models.

What Problem Does This Paper Address?

Renal Cell Carcinoma (RCC) is a highly vascularized cancer, meaning it relies heavily on building new blood vessels to grow and spread. While anti-angiogenic therapies (AATs) are a cornerstone of RCC treatment, many patients eventually develop resistance.

The protein profilin1 (Pfn1) is a key regulator of the actin cytoskeleton, which endothelial cells (the building blocks of blood vessels) need to migrate and proliferate. Pfn1 is significantly overexpressed in the blood vessels of RCC tumors. Previous genetic studies showed that "knocking out" Pfn1 stops tumor growth, but translating this into a clinical therapy requires a drug—specifically, a small molecule that can safely and effectively block Pfn1's function in the complex environment of a living tumor.

Methods

The authors combined medicinal chemistry, computational modeling, and a novel drug-delivery system:

  • Molecular Docking & SAR: Using the GNINA molecular docking software (which utilizes convolutional neural networks), the team modeled how their lead compound, C74, fits into a "cryptic pocket" on Pfn1. They used these insights to synthesize 13 analogs (UP-1 through UP-13) to improve potency.
  • Binding Validation: They used Surface Plasmon Resonance (SPR) and Protein Thermal Shift (PTS) assays to provide the first direct experimental evidence that these molecules physically bind to Pfn1.
  • Ultrasound-Targeted Microbubble Destruction (UTMD): To solve the problem of systemic toxicity and low drug affinity, they encapsulated the drug in lipid microbubbles. These bubbles circulate harmlessly until they reach the tumor, where targeted ultrasound pulses burst them, releasing a high concentration of the drug locally.
  • Biological Assays: The compounds were tested in in vitro endothelial "cord formation" assays (mimicking vessel growth) and in vivo using both Matrigel plug assays and RENCA (murine RCC) tumor models in mice.

Datasets

This study did not utilize large-scale public datasets or introduce new benchmarks. It relied on:

  • Cell Lines: RENCA (murine renal cell carcinoma) and HmVECs (human microvascular endothelial cells).
  • Structural Data: Protein structures for docking were derived from previous molecular dynamics simulations of the Pfn1:actin interface.

Key Insights and Ideas

  • Drugging the "Undruggable": Pfn1-actin interactions are notoriously difficult to target with small molecules. This paper identifies a viable "cryptic pocket" at the protein-protein interface.
  • The Power of the Trifluoromethyl Group: Chemical optimization revealed that replacing a bromine atom (in C74) with a trifluoromethyl group (in UP-6) significantly enhanced anti-angiogenic activity. UP-6 achieved near-complete blockade of vessel formation in vitro at concentrations where C74 was ineffective.
  • Localized Delivery is Essential: Because the current inhibitors are "low-affinity" (binding in the micromolar range), systemic administration would require dangerously high doses. The microbubble/UTMD approach bypasses this, allowing for therapeutic efficacy with minimal systemic exposure.
  • Conformational Destabilization: PTS assays showed that these inhibitors cause a "negative thermal shift," suggesting they might work by destabilizing Pfn1 or inducing a conformational change that prevents it from binding to actin.

Key Results

  • Direct Binding: SPR confirmed C74 binds Pfn1 with a dissociation constant ($K_D$) of ~60 $\mu$M.
  • Tumor Reduction: Direct intratumoral injection of C74 reduced blood vessel density (CD31+ area) in RCC tumors by ~30%.
  • Improved Potency: The optimized analog, UP-6, was significantly more effective than C74 in vivo, reducing endothelial cell infiltration into Matrigel plugs by >50%.
  • Proof-of-Concept for UTMD: Systemic delivery of C74 via microbubbles combined with ultrasound led to a significant reduction in both tumor growth and the number of functional tumor-associated blood vessels.

Limitations and Future Work

  • Affinity: The current lead molecules still bind in the micromolar range. Future medicinal chemistry aims to push this into the nanomolar range for higher potency.
  • Structural Resolution: While docking provides a model, the authors note that X-ray crystallography is needed to confirm the exact atomic arrangements of the drug-protein interaction.
  • Model Complexity: The study primarily used subcutaneous tumor models. The authors plan to move toward orthotopic models (implanting tumors directly into the kidney) to better simulate the human disease environment.
  • Synergy: Future research will explore whether Pfn1 inhibitors can work synergistically with existing FDA-approved anti-angiogenic or immunotherapy drugs.

Summary updated

Abstract

Angiogenesis plays a key role in the development and progression of renal cell carcinoma (RCC). Actin-binding protein profilin-1 (Pfn1) is overexpressed in clear cell RCC predominantly in tumor-associated vascular endothelial cells (ECs). We previously demonstrated that that EC-selective (over)expression of Pfn1 accelerates RCC progression, and conversely, genetic loss of EC-Pfn1 dramatically inhibits tumor angiogenesis impeding tumor initiation and/or progression in RCC, suggesting that Pfn1 could be an actionable therapeutic target in RCC. In this study, we demonstrate that 4,4'-((4-bromophenyl)methylene)bis(3,5-dimethyl-1<i>H</i>-pyrazole), a small molecule that we had previously identified as an inhibitor of Pfn1-actin interaction, directly binds to Pfn1 and attenuates tumor angiogenesis when directly administered into subcutaneous RCC tumors. Next, we undertook a chemical optimization approach to design and synthesize 4,4'-((4-(trifluoromethyl)phenyl)methylene)bis(3,5-dimethyl-1<i>H</i>-pyrazole), a structural analog of our originally identified inhibitor, that exhibits improved anti-angiogenic efficacy <i>in vitro</i> and <i>in vivo</i>. Finally, we demonstrate that Pfn1 inhibitor is amenable to lipid microbubble encapsulation and release in the tumor microenvironment (TME) by ultrasound-mediated disruption of circulating microbubbles to achieve anti-angiogenic and anti-tumor benefit. In summary, our findings suggest that tumor-localized release of Pfn1 inhibitor could be a potential therapeutic strategy in RCC.
BibTeX
@article{gau2025small,
  author = {David Gau and Pooja A. Chawla and Kexin Xu and Niharika Welling and Jacob Antonello and Carla Consoli and Monica Wei and Sara Zdancewicz and Maria Fernanda Laranjeira‐Silva and Chris Varghese and Paul Francoeur and Haibin Shi and Xucai Chen and Anurag N. Paranjape and Flordeliza S. Villanueva and Thomas E. Smithgall and Andrew P. VanDemark and David Ryan Koes and Donna M. Huryn and Partha Roy},
  title = {{Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma}},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.111033},
}
Figure